NasdaqCM:VRDNBiotechs
Is Viridian Therapeutics' (VRDN) Widening Losses Despite Higher Revenue Reframing Its Risk Reward Profile?
In the past, Viridian Therapeutics reported second-quarter 2026 results showing revenue of US$284,000 versus US$75,000 a year earlier, alongside a wider net loss of US$127.12 million and basic loss per share of US$1.05 from continuing operations.
For the first half of 2026, revenue rose to US$425,000 from US$147,000 while net loss increased to US$232.02 million and basic loss per share edged up to US$1.95, highlighting growing expenses outpacing early-stage revenue.
Next, we will examine how...